Creative Medical Technology Holdings (CELZ) Common Equity (2010 - 2026)

Creative Medical Technology Holdings (CELZ) has reported Common Equity for 17 consecutive years, with $8.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 27.12% year-over-year to $8.7 million in Q2 2026; TTM through Jun 2026 was $8.7 million, a 27.12% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, up 18.66% from the prior year.
• Common Equity was $8.7 million for Q2 2026 at Creative Medical Technology Holdings, up from $6.1 million in the prior quarter.
• Over five years, Common Equity peaked at $23.0 million in Q2 2022 and troughed at $2.0 million in Q4 2023.
• A 5-year average of $10.3 million and a median of $8.4 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 6174.45% in 2022 and plunged 87.39% in 2023, its largest moves.
• Over 5 years, Common Equity stood at $15.9 million in 2022, then sank by 87.39% to $2.0 million in 2023, then jumped by 217.07% to $6.3 million in 2024, then advanced by 18.66% to $7.5 million in 2025, then gained by 15.34% to $8.7 million in 2026.
• The last three Common Equity figures came in at $8.7 million (Q2 2026), $6.1 million (Q1 2026), and $7.5 million (Q4 2025), per Business Quant data.